MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202611009517 A) filed by Swami Vivekananda Subharti University, Meerut, Uttar Pradesh, on Jan. 30, for 'a system, a method and a hybrid scaffold platform for ai-designed quinazolinone-racetam derivatives as multi-target therapeutics for drug-resistant epilepsy.'
Inventor(s) include Dr. Nidhi Dhama; and Dr. Aadesh Kumar.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "The present invention discloses AI-designed quinazolinone-racetam hybrid scaffolds engineered as next-generation multi-target therapeutics for drug-resistant epilepsy. The invention integrates a quinazolinone core with a racetam moiety through an optimized linker to achieve simultaneous modulation of AMPA/NMDA glutamatergic receptors, GABA-A inhibitory pathways, and voltage-gated sodium channels. An AI-assisted design platform employing generative modeling, multi-target docking, 6D-QSAR, deep-learning classifiers, and ADMET prediction algorithms enables rational scaffold generation, structural refinement, and activity prioritization. The optimized hybrids exhibit enhanced blood-brain-barrier permeability, improved pharmacokinetic stability, and superior neuroprotective and anticonvulsant potential compared to individual pharmacophores or conventional single-target antiepileptic drugs. The invention further provides methods for computational modeling, synthesis, characterization, and preclinical evaluation of the hybrid molecules. By combining hybrid pharmacophore engineering with AI-driven multi-target optimization, the disclosed invention offers a transformative approach for accelerating CNS drug discovery and delivering potent therapeutic candidates for refractory epilepsy."
Disclaimer: Curated by HT Syndication.
